The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable ...
Pharmaceutical Technology on MSN1d
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLCThe FDA has approved AstraZeneca's Tagrisso (osimertinib) to treat adults with unresectable stage III EGFR-mutated NSCLC.
The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...
ASCO recommends osimertinib consolidation for patients with unresectable, stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation who have completed chemoradiation.
Zacks.com on MSN2d
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLCAstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung ...
Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.
On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor ...
Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib ...
Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.
The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) ...
Tagrisso (osimertinib) for adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) ...
Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback